The Outcome of Tuberculosis Treatment in the Presence of SARS-CoV-2 Anti-RBD Antibody
Infection and Drug Resistance · 2026-07 · Volume 19 · 1-9
DOI: 10.2147/idr.s579272 ↗Kurz gefasst
Fachartikel in der Zeitschrift Infection and Drug Resistance, 2026-07. Verfasst von Heni Muflihah und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Faculty of Medicine, Universitas Islam Bandung, Bandung, Indonesia. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacology, Faculty of Medicine, Universitas Islam Bandung, Bandung, Indonesia.
- Immunoserology and Cell Culture, Research Laboratory, Faculty of Medicine Universitas Islam Bandung, Bandung, Indonesia.
- Department of Public Health, Faculty of Medicine, Universitas Islam Bandung, Bandung, Indonesia.
- Department of Microbiology, Faculty of Medicine, Universitas Islam Bandung, Bandung, Indonesia.
ORCID-Profile: Heni Muflihah, Fajar Awalia Yulianto, Winni Maharani
Zitieren
APA
Muflihah, H., Yulianto, F. A., Maharani, W., & Hanipan, A. R. (2026). The Outcome of Tuberculosis Treatment in the Presence of SARS-CoV-2 Anti-RBD Antibody. Infection and Drug Resistance, Volume 19, 1-9. https://doi.org/10.2147/idr.s579272
Vancouver
Muflihah H, Yulianto FA, Maharani W, Hanipan AR. The Outcome of Tuberculosis Treatment in the Presence of SARS-CoV-2 Anti-RBD Antibody. Infection and Drug Resistance. 2026;Volume 19:1-9. doi:10.2147/idr.s579272
BibTeX
@article{Muflihah2026,
author = {Muflihah, Heni and Yulianto, Fajar Awalia and Maharani, Winni and Hanipan, Anis Rapiq},
title = {The Outcome of Tuberculosis Treatment in the Presence of SARS-CoV-2 Anti-RBD Antibody},
journal = {Infection and Drug Resistance},
year = {2026},
volume = {Volume 19},
pages = {1--9},
doi = {10.2147/idr.s579272}
}
EUVIMED